ATE512364T1 - Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha - Google Patents

Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha

Info

Publication number
ATE512364T1
ATE512364T1 AT03784692T AT03784692T ATE512364T1 AT E512364 T1 ATE512364 T1 AT E512364T1 AT 03784692 T AT03784692 T AT 03784692T AT 03784692 T AT03784692 T AT 03784692T AT E512364 T1 ATE512364 T1 AT E512364T1
Authority
AT
Austria
Prior art keywords
adhesion
amino acid
platelet
gpibα
switch loop
Prior art date
Application number
AT03784692T
Other languages
English (en)
Inventor
Eric Huizinga
Groot Philip De
Shizuko Tsuji
Roland Romijn
Marion Schiphorst
Jan Sixma
Piet Gros
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Application granted granted Critical
Publication of ATE512364T1 publication Critical patent/ATE512364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Push-Button Switches (AREA)
  • Electronic Switches (AREA)
  • Liquid Crystal (AREA)
AT03784692T 2002-08-07 2003-08-06 Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha ATE512364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078277 2002-08-07
PCT/NL2003/000564 WO2004015425A1 (en) 2002-08-07 2003-08-06 Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha

Publications (1)

Publication Number Publication Date
ATE512364T1 true ATE512364T1 (de) 2011-06-15

Family

ID=31502790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784692T ATE512364T1 (de) 2002-08-07 2003-08-06 Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha

Country Status (5)

Country Link
US (1) US7771724B2 (de)
EP (1) EP1527346B1 (de)
AT (1) ATE512364T1 (de)
AU (1) AU2003251238A1 (de)
WO (1) WO2004015425A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527346B1 (de) 2002-08-07 2011-06-08 Ablynx N.V. Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
GB0323728D0 (en) * 2003-10-10 2003-11-12 Royal College Of Surgeons Ie Peptidomimetics and uses thereof
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512097A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
ES2347908T3 (es) 2005-01-14 2010-11-25 Ablynx N.V. PROCEDIMIENTOS Y ENSAYOS PARA DISTINGUIR ENTRE DIFERENTES FORMAS DE ENFERMEDADES Y TRASTORNOS CARACTERIZADOS POR LA TROMBOCITOPENIA Y/O POR LA INTERACCIÓN ESPONTÁNEA ENTRE EL FACTOR DE VON WILLEBRAND (vWF) Y LAS PLAQUETAS.
SI1853631T1 (sl) * 2005-01-24 2016-04-29 Board Of Regents, The University Of Texas System Fuzijski konstrukti, ki zajemajo regijo FC in se vežejo na fosfatidilserine, ter njihova terapevtska uporaba
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
EP2252303A2 (de) * 2008-03-21 2010-11-24 Ablynx NV Von-willebrand-faktor-spezifische bindemittel und verfahren zu ihrer verwendung
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
EP0368684B2 (de) 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
EP2192131A1 (de) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunglobuline ohne Leichtkette
DE69327229T2 (de) 1992-12-11 2000-03-30 The Dow Chemical Co., Midland Multivalente einkettige Antikörper
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
DK0795608T3 (da) * 1994-11-30 2003-07-21 Ajinomoto Kk Antitrombotisk middel og monoklonale anti-von Willebrandfaktor antistoffer
EP0894135B1 (de) 1996-04-04 2004-08-11 Unilever Plc Multivalentes und multispezifisches antigenbindungs protein
AU9262598A (en) 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
EP1027439B1 (de) * 1997-10-27 2010-03-17 Bac Ip B.V. Multivalente antigenbindende proteine
ATE535154T1 (de) * 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
CZ121599A3 (cs) * 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
JP2002529373A (ja) * 1998-10-23 2002-09-10 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド コンホメーション特異的抗ｖｏｎＷｉｌｌｅｂｒａｎｄ因子抗体
EP1002861A1 (de) 1998-10-26 2000-05-24 Unilever Plc Antigenbindungsproteine mit einer Kopplung, die die strukturelle Beweglichkeit einschränkt
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
ES2358576T3 (es) 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
EP2135879A3 (de) 2002-06-28 2010-06-23 Domantis Limited Ligand
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
EP1527346B1 (de) 2002-08-07 2011-06-08 Ablynx N.V. Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
ES2347908T3 (es) 2005-01-14 2010-11-25 Ablynx N.V. PROCEDIMIENTOS Y ENSAYOS PARA DISTINGUIR ENTRE DIFERENTES FORMAS DE ENFERMEDADES Y TRASTORNOS CARACTERIZADOS POR LA TROMBOCITOPENIA Y/O POR LA INTERACCIÓN ESPONTÁNEA ENTRE EL FACTOR DE VON WILLEBRAND (vWF) Y LAS PLAQUETAS.
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases

Also Published As

Publication number Publication date
WO2004015425A1 (en) 2004-02-19
AU2003251238A1 (en) 2004-02-25
EP1527346A1 (de) 2005-05-04
US20050192224A1 (en) 2005-09-01
US7771724B2 (en) 2010-08-10
EP1527346B1 (de) 2011-06-08

Similar Documents

Publication Publication Date Title
ATE512364T1 (de) Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
DE69840412D1 (de) Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
AU2003250825A1 (en) Inhibitors of glycoprotein vi
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
EA201792485A3 (ru) Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты)
PE20010613A1 (es) Antagonistas de la hormona concentradora de la melanina
ATE438624T1 (de) 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
DE60200194D1 (de) Freisetzungssystem von cyclopropenderivaten
DE69833036D1 (de) Sulfonylderivate
ES2061502T3 (es) Nuevos n-heterociclos biciclicos puenteados.
DE602005027213D1 (de) Neue imidazolidinderivate
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
DE59605649D1 (de) Polymerisationsfähige derivate von polyamiden
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
FI941457A0 (fi) Verihiutaleglyproteiini IIb/IIIa:n inhibiittoreina käyttökelpoisia syklisiä yhdisteitä
ATE230398T1 (de) Substituierte heterocyklische derivate, verwendbar als plättchenaggregationshemmstoffe
ATE353082T1 (de) Inhibitoren der gpib-vwf wechselwirkung
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
DE60217854D1 (de) Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung
EA199900552A1 (ru) Асимметрический способ получения бензоксазинонов
ES2169080T3 (es) Inhibidor de la agregacion de plaquetas estimulada por colageno.
CY1107025T1 (el) Ενδιαμεσα για συνθεση ανταγωνιστη lhrh, μεθοδος για την παρασκευη αυτου και μεθοδος για την παρασκευη ανταγωνιστη lhrh

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties